SCHEMBL7868232

SCHEMBL7868232

Cc1nc2cc(-c3ccc4c(c3)CN(C(=O)c3ccc(C)c(C)c3)CCC4)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.47
HDAC6 Q9UBN7 2/20 0.40
HSD11B1 P28845 2/20 0.40
PKM P14618 1/20 0.39
MYC P01106 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ABCB1 P08183 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GFER P55789 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
BRD4 O60885 1/20 0.37
HSP90AA1 P07900 1/20 0.37
ESR2 Q92731 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7868242 0.92 PIK3CA (0.47) PIK3CAHDAC6HSD11B1PKMMYC
SCHEMBL7864958 0.91 PIK3CA (0.49) PIK3CAHDAC6HSD11B1PKMMEN1
SCHEMBL7864356 0.90 PKM (0.47) PIK3CAPKMMEN1KMT2AABCB1
SCHEMBL7870080 0.90 GPR142 (0.47) PIK3CAHDAC6HSD11B1PKMHPGD
SCHEMBL7868233 0.90 PIK3CA (0.45) PIK3CAHDAC6HSD11B1PKMMEN1
SCHEMBL7866569 0.89 GHSR (0.48) PIK3CAALDH1A1KDM4E
SCHEMBL7860217 0.89 PIK3CA (0.44) PIK3CAHDAC6HSD11B1PKMMYC
SCHEMBL7865573 0.88 HDAC6 (0.47) PIK3CAHDAC6HSD11B1MEN1KMT2A
SCHEMBL7867714 0.88 PIK3CA (0.47) PIK3CAHDAC6HSD11B1PKMHPGD
SCHEMBL7868241 0.88 PIK3CA (0.47) PIK3CAHDAC6MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR PIK3CA 16/4885HDAC6 136/4885HSD11B1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.